Advances in Symptom Burden, Risk Stratification, and Treatment of Myelofibrosis – Live

Description

Program Description

---

Click to Go to the Event Registration

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic cell expansion with bone marrow fibrosis. MF has the worst prognosis of the classic Philadelphia chromosome negative MPNs. Although the most frequent cause of death is hematologic transformation and disease progression, patients with MF are at high risk for other competing causes of morbidity and mortality. The considerable heterogeneity of MF translates into a wide range of outcomes. Given this heterogeneity, risk stratification for individualized management becomes essential in disease treatment.

Agenda

---

• Overview risk assessment, symptom burden, cytogenetic and molecular characteristics of myelofibrosis (MF) – Ruben Mesa, MD, FACP
• Case Presentation 1 – Ruben Mesa, MD, FACP
• Discuss recent clinical trials data on emerging treatments and strategies to monitor adverse events in patients with MF – Srdan Verstovsek, MD, PhD
• Case Presentation 2 – Srdan Verstovsek, MD, PhD
• Q&A from the Audience and Panel Discussion – Ruben Mesa, MD, FACP/ Srdan Verstovsek, MD, PhD

Intended Audience

---

Hematologists/oncologists, advanced practice providers, and nurses caring for patients with myelofibrosis

Commercial Supporter

---

Supported by an educational grant from CTI BioPharma Corp..